Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on September 9, 2008
JNCI Journal of the National Cancer Institute 2008 100(18):1331-1332; doi:10.1093/jnci/djn272
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/18/1331-a    most recent
djn272v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chlebowski, R. T.
Right arrow Articles by Col, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chlebowski, R. T.
Right arrow Articles by Col, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

Rowan T. Chlebowski, Nananda Col

Affiliations of authors: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC); Center for Outcomes Research and Evaluation Maine Medical Center, Portland, ME (NC)

Correspondence to: Rowan T. Chlebowski, MD, PhD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W. Carson Street, Torrance, CA, 90502 (e-mail: rchlebowski@gmail.com).

The first 10% of the full text of this article appears below.

Although we concur in general with the interpretation of the CYP2D6 analyses reported by Punglia et al. (1), we believe that their findings need to be placed in a broader context that includes consideration of the toxicity as well as the efficacy of treatments. The Markov model that generated their . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
T. Toyama, H. Yamashita, H. Sugiura, N. Kondo, H. Iwase, and Y. Fujii
No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment
Jpn. J. Clin. Oncol., October 1, 2009; 39(10): 651 - 656.
[Abstract] [Full Text] [PDF]